Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Algernon Pharmaceuticals Inc.
C.AGN
Alternate Symbol(s):
AGNPF
Consumer Cyclical
Healthcare
Advertising Agencies
Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N...
-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Company Website
Add To Watchlist
Bullboard (CSE:AGN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
(6)
•••
DIYPortfolio
X
View Profile
View Bullboard History
Post by
DIYPortfolio
on Sep 07, 2022 11:10am
Algernon Pharmaceuticals AGN.CA 👨🏻⚕️👩🏽⚕️💊💊
Algernon Pharmaceuticals is making great headway with its' new drug Ifenprodil for treatment of Pulmonary Fibrosis
(6)
•••
DIYPortfolio
X
View Profile
View Bullboard History
Post by
DIYPortfolio
on Sep 06, 2022 12:38pm
AGN AGN.ca 👩🏽⚕️👨🏻⚕️👀👀
https://algernonpharmaceuticals.com/medicalgold-ca-algernon-rapidly-advances-clinical-trials-for-two-lead-programs/ Algernon Pharmaceuticals is employing drug repurposing strategies to test
...more
(44)
•••
tdsb
X
View Profile
View Bullboard History
Post by
tdsb
on Sep 03, 2022 9:31pm
C.AGN
Five dollars more to go and we take out the 52 week high. That could happen very fast, this stock is saying I want to be listed on The Nasdaq. I just hope they keep a Canadian listing and also move to
...more
(16)
•••
waves1
X
View Profile
View Bullboard History
Post by
waves1
on Sep 02, 2022 5:10pm
AGN breakout after release of full Phase 2 data set for IPF!
Solid breakout for Algernon Pharmaceuticals ($AGN.c $AGNPF) today, up 15% to $6.90 after reporting positive results from the full data set of its Phase II study of Ifenprodil for IPF and Chronic Cough
...more
(83)
•••
biggonads
X
View Profile
View Bullboard History
Post by
biggonads
on Sep 02, 2022 2:32pm
AGN rated an immediate buy
For reasons including Algernon’s unique position having a mere 2.4M shares OS, 3 main drug candidates all of which likely to be in Phase 2 trials in ‘23, and the positive results from the full data
...more
(83)
•••
biggonads
X
View Profile
View Bullboard History
Post by
biggonads
on Sep 01, 2022 2:19pm
Positive results from full set of phase 2a ifenprodil trials
AGN reports positive results from the full set of their Phase 2a trials evaluating Ifenprodil to treat IPF and chronic cough including statistically significant improvements in measures of cough. This
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 01, 2022 7:00am
New Press Release - Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
VANCOUVER, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to report positive results from the full data set of its...
read article.
(21)
•••
StockHawk1
X
View Profile
View Bullboard History
Post by
StockHawk1
on Aug 31, 2022 6:08pm
AlphaNorth increases its position in AGN.c
Algernon Pharmaceuticals (AGN.c AGNPF) announced last week that its largest shareholder, AlphaNorth Asset Management has increased its ownership position in AGN AlphaNorth acquired 150,000
...more
(6)
•••
DIYPortfolio
X
View Profile
View Bullboard History
Post by
DIYPortfolio
on Aug 31, 2022 5:48pm
AGN.C AGN Algernon Pharmaceuticals 🔥🔥🔥
Can Algernon Pharmaceuticals rise all the way back to previous highs? It's trying
(40)
•••
StockDoctor101
X
View Profile
View Bullboard History
Post by
StockDoctor101
on Aug 30, 2022 2:33pm
AGN names as NIA's favourite biotech stock
AGN.c is up again today and currently sits @ $5.30 (+2.91%). The National Inflation Association recently named AGN.c as their favourate biotech stock suggestion following AlphaNorth Asset Management
...more
(83)
•••
biggonads
X
View Profile
View Bullboard History
Post by
biggonads
on Aug 29, 2022 12:44pm
AGN capitalizes on Mercks failure
AGN has one of the tightest floats of any drug or pharma stock on the market with only 2.3M OS. Major multi-bag potential with significant catalysts in the pipeline including the trials with DMT
...more
(44)
•••
tdsb
X
View Profile
View Bullboard History
Comment by
tdsb
on Aug 26, 2022 10:01pm
RE:AGN.c +40% this week
This is the first Biotech stock I have owned, such a low float can bring surprises in share price. I am excited about the prospects for this company. It is an interesting play and I look forward to
...more
(268)
•••
stockpatrol
X
View Profile
View Bullboard History
Post by
stockpatrol
on Aug 26, 2022 6:46pm
AGN.c +40% this week
AGN.c +40% this week https://twitter.com/Psych_Fin/status/1563268411303788545 AGN.c quickly rising in popularity recently becoming NIA’s top biotech stock. As well as their
...more
(83)
•••
biggonads
X
View Profile
View Bullboard History
Post by
biggonads
on Aug 26, 2022 12:41pm
Take note when CAN's #1 hedge fund company doubles ownership
Definitely noteworthy when Canada’s #1 most successful hedge fund company, AlphaNorth Asset Management, nearly doubled its ownership position in AGN to 13%, believing recent weakness in share price
...more
(43)
•••
Stockydoc
X
View Profile
View Bullboard History
Post by
Stockydoc
on Aug 25, 2022 3:47pm
NIA's favourite biotech stock - AGN.c
NIA has announced its favourite biotech stock as AGN.c. In addition, AGN's largest shareholder, AlphaNorth Asset Management increased their stake in AGN up to 13% the other day. AGN is moving
...more
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
GameSquare to Report Q3 2024 Financial Results on November 14, 2024
Options Trading for Retiring: Key Strategies in Balancing Retirement Income
Learn About a Mining Portfolio of More Than 250 Projects and Royalties Across North America
Have you held units of a TD mutual fund (other than through a discount broker)? Learn more.
Nanalysis Announces Third Quarter 2024 Conference Call